"Max’s profit surges 74% — Is this India’s next healthcare multibagger?"

📊 Q2 FY26 Financial Highlights - Net Profit: ₹491 crore, up 74.3% YoY - Revenue: ₹2,135 crore, up 25% YoY - EBITDA: ₹575 crore, up 17.5% YoY; margin improved to 26.9% - EPS: ₹5.02 vs ₹2.88 YoY - International Patient Revenue: ₹231 crore, up 25% YoY, now 9% of hospital revenue ⚠️ Investor Watchouts - Valuation Premium: Trading at high multiples due to strong growth; any slowdown could trigger correction - Integration Risk: Ongoing merger of CRL and JHL subsidiaries and Noida hospital integration may impact short-term margins - Regulatory Sensitivity: Healthcare sector remains exposed to pricing and compliance regulations 📈 Stock Impact & Technical Levels - Current Price: ₹1,103.10 (as of Nov 14, 2025) - Support Zone: ₹1,080–₹1,060 (recent swing lows and psychological level) - Resistance Zone: ₹1,120–₹1,150 (recent highs and breakout zone) - Momentum: Positive; strong results and Nifty inclusion support bullish sentiment 🚀 Future Growth & Strategic Planning - Brownfield Expansion: New capacities at Max Mohali, Nanavati-Max, and Max Smart underway - International Focus: Continued growth in medical tourism and high-margin international patient segment - Digital & OPD Growth: Higher outpatient footfall and digital health initiatives driving operational efficiency